[Future aspects of modern Parkinson therapy]

Abstract

The present limitations of modern antiparkinsonian therapy (decreasing efficacy and increase of side-effects with advancing age and disease duration, lack of causal and neuroprotective therapies) require a multidisciplinary approach in basic, preclinical and clinical research. New substances with higher therapeutic potency and less side-effects, progress in functional stereotaxy, rehabilitation and restorative neurology, and new concepts in neurotransplantation as well as improved knowledge of etiology and pathophysiology are needed for an improvement of therapy.